File(s) under permanent embargo
Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy
journal contributionposted on 2023-05-18, 10:46 authored by Dyck, PJ, Bruce TaylorBruce Taylor, Davies, JL, Mauermann, ML, Litchy, WJ, Klein, CJ, Dyck, PJB
Intravenous immunoglobulin [IVIg], plasma exchange [PE], and corticosteroids are efficacious treatment in chronic inflammatory demyelinating polyneuropathy [CIDP]. IVIg is effective in multifocal motor neuropathy [MMN]. NIS, NIS-weakness, sum scores of raw amplitudes of motor fiber (CMAPs) amplitudes, and Dyck/Rankin score provided reliable measures to detect and scale abnormality and reflect change; they are therefore ideal for office management of response-based immunotherapy (R-IRx) of CIDP. Using efficacious R-IRx, a large early and late therapeutic response (≥ one-fourth were in remission or had recovered) was demonstrated in CIDP. In MMN only an early improvement with late non-significant worsening was observed. The difference in immunotherapy response supports a fundamental difference between CIDP (immune attack on Schwann cells and myelin) and MMN (attack on nodes of Ranvier and axons).
Publication titleMuscle and Nerve
Department/SchoolMenzies Institute for Medical Research
PublisherJohn Wiley & Sons Inc
Place of publication111 River St, Hoboken, USA, Nj, 07030
Rights statementCopyright 2015 Wiley Periodicals, Inc.